Disney acquires 21st Century Fox in a $52 billion landmark deal.

Amy Hamilton

2017-12-15 07:42:00 Fri ET

Disney acquires 21st Century Fox in a $52 billion landmark deal. This deal has a total value of about $66 billion while Disney assumes $14 billion of Fox's net debt. Bob Iger will remain Disney's CEO and key chairman to oversee this mega media integration until December 2021. In fact, the resultant Disney-Fox M&A deal will give Disney more media content when Disney launches its own video streaming service on demand.

The Economist suggests that as the Mouse acquires the Fox, this mega media deal will accelerate Hollywood's modern transformation from a film capital to a video streaming service town. Disney's ambitious acquisition of Fox and its own affiliates remains subject to approval by their shareholders and regulators, and this acquisition combines Disney and Fox as powerful film studios. Franchises such as Avatar and X-Men will join Disney's formidable library of Marvel titles, Pixar animation hits, and Star Wars films. In addition, Disney gains dozens of cable networks to add to its own collection, as well as Fox's equity stake in Sky, a European satellite broadcaster.

CNBC and CNN both report that if U.S. antitrust laws approve this mega media deal, it means stiffer competition for video streaming service providers such as Netflix, Amazon, and YouTube. As a consequence, film viewers and consumers benefit much from better content distribution and scale in this broad horizontal consolidation across the media industry landscape.

 


If any of our AYA Analytica financial health memos (FHM), blog posts, ebooks, newsletters, and notifications etc, or any other form of online content curation, involves potential copyright concerns, please feel free to contact us at service@ayafintech.network so that we can remove relevant content in response to any such request within a reasonable time frame.

Blog+More

The new antitrust enforcement paradigm

Joseph Corr

2023-10-14 10:32:00 Saturday ET

The new antitrust enforcement paradigm

Jonathan Baker frames the current debate over antitrust merger review and enforcement in America. Jonathan Baker (2019)   The antitrust paradi

+See More

President Trump criticizes the potential media merger between AT&T and Time Warner.

Chanel Holden

2017-11-05 09:45:00 Sunday ET

President Trump criticizes the potential media merger between AT&T and Time Warner.

President Trump criticizes the potential media merger between AT&T and Time Warner, the latter of which owns the anti-Trump media network CNN. President

+See More

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

Jacob Miramar

2019-01-10 17:31:00 Thursday ET

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history. The resultant biopharma goliath would be

+See More

Nobel Laureate Joseph Stiglitz maintains that globalization only works for a few elite groups.

Becky Berkman

2019-08-09 18:35:00 Friday ET

Nobel Laureate Joseph Stiglitz maintains that globalization only works for a few elite groups.

Nobel Laureate Joseph Stiglitz maintains that globalization only works for a few elite groups; whereas, the government should now reassert itself in terms o

+See More

China President Xi tries to ease trade tension between America and China in his Boao presidential address.

Monica McNeil

2018-04-02 07:33:00 Monday ET

China President Xi tries to ease trade tension between America and China in his Boao presidential address.

China President Xi JinPing tries to ease trade tension between America and China in his presidential address at the annual Boao forum. In his vulnerable att

+See More

Several pharmaceutical companies now switch their primary focus from generic prescription drugs to medical specialties.

Rose Prince

2018-10-15 09:33:00 Monday ET

Several pharmaceutical companies now switch their primary focus from generic prescription drugs to medical specialties.

Several pharmaceutical companies now switch their primary focus from generic prescription drugs to medical specialties such as cardiovascular medications an

+See More